MDMA-Assisted Therapy: What the Evidence Shows

This page sets out the evidence on MDMA-assisted therapy for post-traumatic stress disorder as it stands in July 2026, whether you are asking for yourself, for someone you care about, or to make sense of a confusing news cycle. MDMA, the compound also known as ecstasy in recreational use, has been studied as a supervised treatment for PTSD, delivered alongside structured psychotherapy. The clinical results are among the strongest in the whole psychedelic field, and yet the most-watched regulator in the world declined to approve it in 2024. Holding both facts at once is the honest starting point. This is a clinical and legal summary only: it does not describe doses, preparation, or what a session feels like, and it is not a guide to obtaining or using MDMA.

What it is

MDMA (3,4-methylenedioxymethamphetamine) is not a classic psychedelic like psilocybin; it is an entactogen that increases release of serotonin, dopamine and noradrenaline and tends to reduce fear responses while increasing feelings of trust and openness. In research for PTSD it is given in a small number of supervised dosing sessions, typically two or three spaced weeks apart, embedded in a longer course of preparatory and integration psychotherapy, usually delivered by a two-therapist team. The medicine is administered within a structured programme of psychological support and psychotherapy, not as a standalone drug (Blossom compound overview).

Regulatory status, stated plainly: MDMA-assisted therapy is not an approved medicine anywhere in the European Union. It has no EMA marketing authorisation and no national approval for general medical use. It is investigational, lawful primarily inside authorised clinical trials, with one relevant European exception: Switzerland's limited medical use program, under which a small number of authorised physicians may treat named patients with MDMA (alongside psilocybin and LSD) when standard treatments have failed. There is no equivalent MDMA compassionate use or national framework elsewhere in Europe; Germany's compassionate use program and Czechia's new national framework both cover psilocybin, not MDMA.

What the evidence shows

The evidence tiers are unusually stark here: one indication with strong Phase 3 data, and a regulatory rejection sitting on top of it.

Approved and established use: none

There is no established, approved clinical use of MDMA-assisted therapy in Europe. No regulator has authorised it as a medicine: not the EMA, and not, as of 2026, the US FDA. No indication sits in an "established practice" tier. Everything below is research evidence.

PTSD — the largest body of clinical evidence

PTSD is the indication with real Phase 3 depth. The program run by MAPS (through its public-benefit sponsor, later Lykos Therapeutics) produced two pivotal randomised, double-blind, placebo-controlled trials:

• MAPP1, published in Nature Medicine in 2021, randomised 90 participants with severe PTSD and found MDMA-assisted therapy produced a significant reduction in CAPS-5 symptom scores versus placebo with therapy (P<0.0001, effect size d≈0.9) (Mitchell et al., Nature Medicine 2021).
• MAPP2, published in Nature Medicine in 2023, randomised 104 participants with moderate-to-severe PTSD and replicated the benefit: significant improvement in PTSD symptoms and in functional impairment versus placebo with therapy over 18 weeks. At the study endpoint 86.5% of the MDMA group met the prespecified threshold for clinically meaningful improvement and 71.2% no longer met PTSD criteria. The placebo-with-therapy group also improved considerably, so the treatment effect has to be read from the between-group comparison rather than the MDMA-group percentages alone (Mitchell et al., Nature Medicine 2023).

Two positive Phase 3 trials in a hard-to-treat condition provide substantial evidence of a potentially meaningful treatment effect. How reliable and how large that effect is remains uncertain: functional unblinding, expectancy and selection bias, limited independent replication and unresolved questions about the contribution of the accompanying psychotherapy all bear on the answer. A living systematic review of MDMA-assisted therapy trials for PTSD continues to track the pooled picture (medRxiv living review, 2026). Yet, as the next section makes clear, strong published data did not translate into approval. The reasons matter.

Depression and other uses — early evidence

Outside PTSD, MDMA-assisted therapy has been explored in a small proof-of-principle study for major depressive disorder and in early work on social anxiety in autistic adults and alcohol use disorder. These are small, early studies and do not support any firm clinical conclusion (MDMA-AT for MDD proof-of-principle, 2025). The honest label is "early"; PTSD is the only indication where the evidence is strong.

What is being studied now — and the FDA rejection

Any honest account of MDMA-assisted therapy in 2026 has to centre the regulatory story, because it, not the trial data, is what changed the field.

The FDA rejection (August 2024): in June 2024 an FDA advisory committee voted that the submitted evidence did not adequately demonstrate effectiveness, and that the benefits did not outweigh the risks under the proposed risk-management plan. The FDA subsequently reached its own decision and declined to approve MDMA-assisted therapy for PTSD, issuing a Complete Response Letter (CRL) to Lykos Therapeutics in August 2024. The FDA made the letter public in September 2025. The core concerns were incomplete collection of safety (adverse-event) data, insufficient evidence of durability, and difficulty interpreting results: the functional unblinding common to psychedelic trials, where participants generally knew whether they had received MDMA, could have inflated the apparent effect. The FDA indicated that an additional Phase 3 study would be needed (Psychedelic Alpha CRL coverage; HCPLive on the CRL; MAPS statement).

What happened to the sponsor: the rejection was a serious blow. Lykos cut its workforce dramatically, restructured, and later rebranded as Resilient Pharmaceuticals, accepting the FDA's view that reviving the application requires a fresh Phase 3 trial — work the company has said would take two years or more (Psychedelic Alpha, one year on; FierceBiotech on the new trial; Lykos/Resilient background).

What it means for Europe: the FDA decision is a US regulatory action. The EMA reaches its own conclusions on its own timeline, and the CRL does not directly bind European regulators, but the practical effect crossed the Atlantic. The same blinding, durability and safety-reporting questions apply to the same underlying trials, so the bar for a European application has, if anything, risen. Some observers framed the CRL as a needed reset, a chance for the field to run tighter trials, rather than a verdict that MDMA does not work (STAT, FDA reset; Labiotech). There is no MDMA marketing authorisation in Europe, and none is imminent.

Recruiting and planned research: European MDMA research is active but modest. A MAPS-linked Phase 2 study of MDMA-assisted therapy for PTSD ran across sites in the UK, Germany, Portugal, Norway, the Czech Republic and the Netherlands and has completed (NCT04030169). Separately, in the Netherlands a state commission in 2024 recommended expediting access, and the Dutch government has earmarked funding toward a large naturalistic study of MDMA-assisted therapy for PTSD. That is an important national signal, though as of July 2026 recruitment specifics for the study were not confirmed on the public registries (Psychedelic Alpha, Dutch committee; OPEN Foundation on the Dutch report). Anyone considering participation should verify current status on ClinicalTrials.gov and the EU Clinical Trials Information System, and read our clinical trials guide.

Safety and who should not take it

MDMA has meaningful acute physiological effects, and the supervised, screened trial model exists precisely to manage them. It is not suitable for everyone. Trials of MDMA-assisted therapy have typically excluded people with:

• A personal or family history of psychosis, or bipolar I disorder, on the concern that treatment could destabilise these conditions.
• Significant or uncontrolled cardiovascular disease, including uncontrolled hypertension, because MDMA raises heart rate, blood pressure and body temperature, which is why cardiovascular screening is standard.
• Certain concurrent medications. Many trials require changes to antidepressants and other psychoactive medicines: SSRIs and SNRIs may blunt MDMA's effects and complicate interpretation of the response, and MAO inhibitors are a major contraindication because of potentially dangerous toxicity. Stimulants, drugs affecting MDMA metabolism (including some antivirals), and medicines acting on blood pressure, cardiac rhythm or the seizure threshold are also relevant. Any medication change must be managed by the prescribing clinician.
• Pregnancy or breastfeeding, significant liver disease, and in most protocols being under 18.

During and shortly after a session, transient effects such as elevated blood pressure and heart rate, jaw tension, nausea, anxiety and difficult emotional material are expected and are part of what the supervised, two-therapist setting is designed to hold and monitor. Because trauma-focused work can be intense, the model builds in preparation and integration sessions rather than treating the drug in isolation. Serious adverse events were uncommon in the Phase 3 trials. But the FDA's criticism that adverse-event data collection was incomplete is a reminder that safety reporting itself, not just the raw risk, is part of what regulators judge. Careful psychiatric and medical screening, controlled administration, physiological monitoring, therapist safeguarding, clear professional boundaries and follow-up care may reduce risk, but they do not eliminate it — and the safety profile remains incompletely characterised, because the trials have been relatively small, highly selective and inconsistent in how they collected and reported adverse events. A provider willing to treat without that assessment is a warning sign.

Legal status and how access works in Europe

The default position across Europe is clear: MDMA is a controlled substance, and supervised MDMA-assisted therapy is lawful essentially only inside an authorised clinical trial. Trials are free, ethics-committee supervised and governed by participant rights, but screening is strict and enrolment is never guaranteed; our clinical trials guide explains phases, placebo and consent. Because MDMA-assisted therapy is investigational, it is not reimbursed by health systems outside research; our reimbursement map shows how coverage works across the continent for the therapies that are approved.

The one standing exception is Switzerland, whose limited medical use program lets a small number of authorised physicians treat named patients with MDMA when standard treatments have failed. It is usually self-paid, carries long waitlists, and is detailed in our Switzerland access guide. For completeness: Germany's compassionate use program and Czechia's new national framework are real, but both cover psilocybin, not MDMA; see our Germany access guide and Czechia access guide. No MDMA-specific national access route exists elsewhere in Europe.

To see what might be available where you are, start with our eligibility check.

Frequently asked questions

Can I legally get MDMA-assisted therapy in Europe today?

For almost everyone, only by joining a clinical trial. MDMA-assisted therapy has no EMA marketing authorisation and no general medicinal approval in the EU, so supervised therapy outside research is not generally lawful. Switzerland operates a separate exceptional-authorisation mechanism for certain controlled substances, including MDMA, in named patients: it runs through a small number of authorised physicians, is usually self-paid, and carries long waitlists. Anyone offering MDMA therapy commercially outside these routes is operating illegally.

If the trials were positive, why did the FDA say no?

The FDA did not conclude that MDMA has no therapeutic effect. Its August 2024 Complete Response Letter concluded that the submitted programme did not provide sufficiently reliable evidence of effectiveness and safety to support approval, and cited the gaps it wanted addressed: incomplete adverse-event data collection, insufficient durability evidence, and difficulty interpreting results because participants generally knew whether they received MDMA (a blinding problem common to psychedelic trials). The FDA asked for an additional Phase 3 study. Positive published trials and regulatory approval are not the same thing.

Does the FDA decision affect Europe?

Not directly. The EMA decides on its own timeline and is not bound by an FDA letter. But the underlying concerns apply to the same trials, so the evidentiary bar in Europe is high, and there is no European approval and none imminent. The decision reshaped expectations on both sides of the Atlantic.

Is MDMA-assisted therapy safe?

Under clinical supervision, with proper screening, serious harms were uncommon in the trials. The key safeguards are cardiovascular and psychiatric screening (people with significant heart disease or a history of psychosis or bipolar disorder are generally excluded), management of interacting medications, and the supervised two-therapist setting with preparation and integration. It is not a treatment to pursue outside a clinical, screened environment.

Is this the same as taking ecstasy?

No. The trials use pharmaceutical-grade MDMA of known composition, given a small number of times under medical supervision within a structured psychotherapy program, with screening and monitoring. Recreational ecstasy is unregulated in composition and setting and is not a treatment. This page addresses only the clinical and regulatory picture.

Sources

1. Mitchell JM et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (MAPP1). Nature Medicine 2021
2. Mitchell JM et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial (MAPP2). Nature Medicine 2023
3. Living systematic review and meta-analysis of MDMA-assisted therapy trials for PTSD (medRxiv, 2026)
4. Psychedelic Alpha: FDA publishes Lykos Therapeutics' MDMA Complete Response Letter
5. HCPLive: FDA releases CRL detailing safety concerns for MDMA-assisted therapy in PTSD
6. MAPS: statement on FDA's public release of the CRL
7. Psychedelic Alpha: one year after the FDA's MDMA rejection
8. FierceBiotech: Lykos accepts FDA's view that a fresh Phase 3 trial is required
9. STAT: FDA criticism of MDMA-assisted therapy is an opportunity for psychedelic medicine
10. Labiotech: with Lykos CRL now public, FDA opens new era of accountability
11. Psychedelic Alpha: Dutch committee seeks to expedite MDMA-assisted therapy for PTSD
12. OPEN Foundation: key insights from the Dutch state commission MDMA report
13. ClinicalTrials.gov: NCT04030169 — European Phase 2 MDMA-assisted therapy for PTSD (completed)
14. EU Clinical Trials Information System (CTIS)
15. Psychedelic Alpha: worldwide psychedelic laws tracker

This article is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. It does not provide guidance on obtaining, preparing or using any substance. The evidence and regulatory picture change quickly; always verify current details with official registries and a licensed clinician who knows your history. If you are in crisis, contact your local emergency number or a crisis line immediately.

Medically reviewed by Dr. Amy Reichelt, PhD, on 31 July 2026.